MX2022000209A - Uso de ibrutinib en el tratamiento del sindrome de bronquiolitis obliterante. - Google Patents
Uso de ibrutinib en el tratamiento del sindrome de bronquiolitis obliterante.Info
- Publication number
- MX2022000209A MX2022000209A MX2022000209A MX2022000209A MX2022000209A MX 2022000209 A MX2022000209 A MX 2022000209A MX 2022000209 A MX2022000209 A MX 2022000209A MX 2022000209 A MX2022000209 A MX 2022000209A MX 2022000209 A MX2022000209 A MX 2022000209A
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- host disease
- methods
- versus host
- graft versus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
Se describen aquí métodos para tratar y evitar enfermedad crónica de injerto versus anfitrión impulsada por aloanticuerpo (cGVHD). Los métodos incluyen administrar a un individuo en necesidad de los mismos ibrutinib para tratar y evitar enfermedad de injerto versus anfitrión impulsada por aloanticuerpo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361910944P | 2013-12-02 | 2013-12-02 | |
US201461973178P | 2014-03-31 | 2014-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022000209A true MX2022000209A (es) | 2022-02-03 |
Family
ID=53270044
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016006955A MX2016006955A (es) | 2013-12-02 | 2014-12-02 | Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo. |
MX2022000209A MX2022000209A (es) | 2013-12-02 | 2016-05-27 | Uso de ibrutinib en el tratamiento del sindrome de bronquiolitis obliterante. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016006955A MX2016006955A (es) | 2013-12-02 | 2014-12-02 | Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo. |
Country Status (14)
Country | Link |
---|---|
US (4) | US20150157634A1 (es) |
EP (1) | EP3076975A4 (es) |
JP (4) | JP2017501140A (es) |
KR (2) | KR20160085817A (es) |
CN (2) | CN105939717B (es) |
AU (3) | AU2014360758B2 (es) |
BR (1) | BR112016012158A2 (es) |
CA (2) | CA2932255C (es) |
EA (1) | EA201691020A1 (es) |
IL (3) | IL292522A (es) |
MX (2) | MX2016006955A (es) |
PH (1) | PH12016501051A1 (es) |
TW (3) | TW202228700A (es) |
WO (1) | WO2015084857A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI662964B (zh) | 2012-06-04 | 2019-06-21 | 美商製藥有限責任公司 | 布魯頓氏酪胺酸激酶抑制劑之結晶形式 |
TWI620565B (zh) * | 2013-10-25 | 2018-04-11 | 製藥公司 | 治療及預防移植物抗宿主病之方法 |
AR102871A1 (es) | 2014-12-03 | 2017-03-29 | Pharmacyclics Llc | Métodos de tratamiento de fibrosis |
US20190070145A1 (en) * | 2016-03-22 | 2019-03-07 | Mayo Foundation For Medical Education And Research | Using fatty acid synthase inhibitors to treat fibrosis |
WO2018002958A1 (en) * | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
WO2018075888A1 (en) * | 2016-10-21 | 2018-04-26 | Regents Of The University Of Minnesota | Materials and methods for treating or preventing graft-versus-host-disease |
CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
WO2022119931A1 (en) * | 2020-12-01 | 2022-06-09 | City Of Hope | Prevention and treatment of graft-versus-host disease (gvhd) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060182723A1 (en) * | 2005-01-25 | 2006-08-17 | Spellberg Brad J | Methods for treating refractory infections in neutropenic individuals |
CA2636696A1 (en) * | 2006-01-13 | 2007-08-02 | Pharmacyclics, Inc. | Inhibitors of tyrosine kinases and uses thereof |
EP2201840B1 (en) * | 2006-09-22 | 2011-11-02 | Pharmacyclics, Inc. | Inhibitors of Bruton's Tyrosine Kinase |
CN102159214A (zh) * | 2008-07-16 | 2011-08-17 | 药品循环公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
JP5656976B2 (ja) * | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | ピロロトリアジン化合物 |
AU2010286361A1 (en) * | 2009-08-31 | 2012-03-15 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
US20120071497A1 (en) * | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
MY191929A (en) * | 2010-06-03 | 2022-07-18 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
KR20140058543A (ko) * | 2011-07-08 | 2014-05-14 | 노파르티스 아게 | 신규 피롤로 피리미딘 유도체 |
ES2681050T3 (es) * | 2012-04-11 | 2018-09-11 | Acerta Pharma B.V. | Inhibidores de la tirosina quinasa de Bruton para la movilización hematopoyética |
WO2013177596A2 (en) * | 2012-05-25 | 2013-11-28 | Sloan Kettering Institute For Cancer | Methods for treating gi syndrome and graft versus host disease |
CN104994875B (zh) * | 2013-02-15 | 2018-10-09 | 免疫医疗公司 | 嵌合和人源化抗组蛋白抗体 |
TWI620565B (zh) * | 2013-10-25 | 2018-04-11 | 製藥公司 | 治療及預防移植物抗宿主病之方法 |
TWI810588B (zh) * | 2015-03-03 | 2023-08-01 | 美商製藥公司 | 布魯東氏(bruton’s)酪胺酸激酶抑制劑之醫藥調配物 |
-
2014
- 2014-12-02 CA CA2932255A patent/CA2932255C/en active Active
- 2014-12-02 EA EA201691020A patent/EA201691020A1/ru unknown
- 2014-12-02 TW TW110135203A patent/TW202228700A/zh unknown
- 2014-12-02 CA CA3210338A patent/CA3210338A1/en active Pending
- 2014-12-02 KR KR1020167015178A patent/KR20160085817A/ko active IP Right Grant
- 2014-12-02 JP JP2016536248A patent/JP2017501140A/ja not_active Ceased
- 2014-12-02 AU AU2014360758A patent/AU2014360758B2/en active Active
- 2014-12-02 US US14/558,297 patent/US20150157634A1/en not_active Abandoned
- 2014-12-02 EP EP14867905.3A patent/EP3076975A4/en active Pending
- 2014-12-02 MX MX2016006955A patent/MX2016006955A/es unknown
- 2014-12-02 IL IL292522A patent/IL292522A/en unknown
- 2014-12-02 CN CN201480074674.4A patent/CN105939717B/zh active Active
- 2014-12-02 BR BR112016012158A patent/BR112016012158A2/pt not_active Application Discontinuation
- 2014-12-02 TW TW103141826A patent/TWI743019B/zh active
- 2014-12-02 CN CN201910760757.3A patent/CN110478353B/zh active Active
- 2014-12-02 TW TW112113060A patent/TW202402295A/zh unknown
- 2014-12-02 KR KR1020237021643A patent/KR20230104754A/ko not_active Application Discontinuation
- 2014-12-02 WO PCT/US2014/068177 patent/WO2015084857A1/en active Application Filing
-
2016
- 2016-05-18 IL IL245715A patent/IL245715A0/en unknown
- 2016-05-27 MX MX2022000209A patent/MX2022000209A/es unknown
- 2016-06-02 PH PH12016501051A patent/PH12016501051A1/en unknown
-
2017
- 2017-12-01 US US15/829,087 patent/US20180078558A1/en not_active Abandoned
-
2020
- 2020-02-18 JP JP2020025682A patent/JP2020105181A/ja not_active Ceased
- 2020-06-26 AU AU2020204276A patent/AU2020204276A1/en not_active Abandoned
- 2020-07-29 US US16/942,151 patent/US20210177854A1/en not_active Abandoned
- 2020-08-12 IL IL276683A patent/IL276683A/en unknown
-
2022
- 2022-04-29 US US17/733,419 patent/US20230100137A1/en not_active Abandoned
- 2022-06-02 AU AU2022203810A patent/AU2022203810A1/en active Pending
- 2022-11-25 JP JP2022188655A patent/JP2023029899A/ja not_active Ceased
-
2024
- 2024-01-26 JP JP2024010504A patent/JP2024072291A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
PH12016501051A1 (en) | Methods of treasting and preventing alloantibody driven chronic graft versus host disease | |
EA201790398A1 (ru) | Способы лечения заболевания печени | |
CL2015003731A1 (es) | Inhibidores de bromodominios | |
MX2015014431A (es) | Monoterapia con glucopiranosil lipido a para usarse en el tratamieto del cancer. | |
TN2015000353A1 (en) | Newcastle disease viruses and uses thereof | |
PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
CR20150046A (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
MX2015002371A (es) | Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos. | |
PH12014501844B1 (en) | Peptidomimetic macrocycles | |
MX2015009105A (es) | Composiciones en solucion solida y su uso en inflamacion cronica. | |
MX366317B (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
AU2012229123A8 (en) | Methods of treating breast cancer with anthracycline therapy | |
NI201500150A (es) | TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método | |
HK1215540A1 (zh) | 用於治療或預防疾病的因子 蛋白、因子 蛋白及其抑制劑 | |
MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. | |
IN2014DN08385A (es) | ||
MX2016005473A (es) | Metodos y composiciones para mejorar la funcion renal. | |
EA201690445A1 (ru) | Лечение рака | |
MX369455B (es) | Métodos mejorados para tratamiento de grano con ozono. | |
ES2586805T3 (es) | Análogos de péptidos para tratar enfermedades y trastornos | |
BR112013032188A2 (pt) | composição, produto e método para tratar pacientes com hepatite c crônica | |
UA86338U (ru) | Способ лечения беременных с гестационным диабетом |